Saturday 17 October 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023. In the quarter to June 2026, revenue grew 147.7%, EPS grew 98.4% and free cash flow fell 45.0%, each against the same quarter a year earlier.
2.77
0.27
−8.88%
Follow ELAB
PMGC Holdings Inc. (ELAB) P/E ratio
PMGC Holdings Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.2× (March 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.2×
Ten-year median
0.0×
Current reading's percentile
74
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XRTX XORTX Therapeutics Inc. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| NTBLQ Notable Labs, Ltd. compare | n/m |
| ELAB PMGC Holdings Inc. | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)